Hypothesis

Chronic oxidation of tetrahydrobiopterin (BH4) to dihydrobiopterin (BH2) shifts endothelial nitric oxide synthase (eNOS) toward uncoupling, increasing superoxide production that nitrosylates and stabilizes miR‑126 within endothelial‑derived exosomes. These exosomes then transfer miR‑126 to neighboring endothelial cells, suppressing eNOS expression and perpetuating a paracrine loop of endothelial dysfunction and arterial stiffening. Restoring the BH4:BH2 ratio—via sepiapterin supplementation combined with timed high‑intensity hypoxic exercise—will break this loop, reduce exosomal miR‑126 loading, and improve flow‑mediated dilation (FMD) more effectively than either intervention alone.

Mechanistic Rationale

• BH4 is an essential eNOS cofactor; its oxidation uncouples eNOS, generating superoxide that reacts with NO to form peroxynitrite, further depleting BH4 ([2]).
• Superoxide and peroxynitrite can S‑nitrosylate specific RNA‑binding proteins, altering miRNA sorting into exosomes; miR‑126, a key regulator of eNOS transcription, is known to be enriched in endothelial exosomes under oxidative stress.
• Exosomal miR‑126 delivered to recipient endothelial cells represses eNOS mRNA translation, lowering NO bioavailability and promoting VSMC calcification and ECM remodeling, thus increasing arterial stiffness ([1]).
• High‑intensity hypoxic exercise acutely elevates shear stress and transiently increases eNOS coupling, while sepiapterin provides a intracellular BH4 precursor that resists oxidation, together favoring a high BH4:BH2 ratio ([3][4]).
• The combined approach should lower oxidative modification of miR‑126‑binding proteins, decrease exosomal miR‑126 export, and restore endothelial NO production.

Testable Predictions

1. Middle‑aged adults receiving sepiapterin (10 mg kg⁻¹ day⁻¹) plus 3 sessions/week of 4‑minute hypoxic intervals (FiO₂ ≈ 14 %) will exhibit a significantly higher plasma BH4:BH2 ratio after 8 weeks than those receiving either monotherapy or placebo.
2. The combined therapy will reduce the concentration of miR‑126‑positive exosomes isolated from peripheral blood by ≥30 % relative to baseline, whereas monotherapies will produce ≤10 % change.
3. Improvements in brachial artery FMD (% diameter change) will correlate inversely with exosomal miR‑126 levels (r < ‑0.5) and directly with BH4:BH2 ratio (r > 0.5).
4. Pulse wave velocity (cfPWV) will decrease only in the combination group, reflecting disrupted endothelial dysfunction–stiffness feedback.

Experimental Design

• Design: Randomized, double‑blind, placebo‑controlled 2×2 factorial trial (n = 80; 20 per arm: placebo, sepiapterin alone, hypoxic exercise alone, combination).
• Population: Adults aged 45‑65 with baseline cfPWV > 8 m s⁻¹ or FMD < 6 % (early vascular aging).
• Interventions: Daily oral sepiapterin; hypoxic exercise performed on a treadmill with normobaric hypoxia (FiO₂ ≈ 14 %) for 4 × 4‑min bouts at 85‑90 % HRmax, 3 × week.
• Outcomes (baseline, 4 w, 8 w): plasma BH4/BH2 (HPLC), exosomal miR‑126 (qPCR after ultracentrifugation), brachial artery FMD (ultrasound), cfPWV (tonometry), nitrotyrosine (oxidative stress marker), and circulating ADMA.
• Statistical Analysis: Two‑way ANOVA for interaction effects; Pearson correlation for biomarker‑outcome relationships; intention‑to‑treat.

Potential Implications

If validated, this hypothesis would identify a redox‑sensitive exosomal miRNA mechanism that amplifies endothelial dysfunction beyond cell‑autonomous eNOS uncoupling. It would justify a dual‑target strategy—stabilizing BH4 while reducing oxidative miRNA loading—to reverse early vascular aging, offering a biomarker‑driven (BH4:BH2 ratio, exosomal miR‑126) approach for longevity risk models that currently rely on isolated cfPWV or FMD measurements.